T he current obesity epidemic, which is partly induced by our increasingly sedentary lifestyles and high-fat diets, is expected to result in type 2 diabetes mellitus, considerable downstream morbidity, and mortality, and increasing costs to healthcare systems around the world 1, 2 . The incidence of type 2 diabetes is increasing at a worrisome rate and is expected to double within the next few decades 3 . In recent years, despite advances in our understanding of obesity, the molecular mechanisms underlying individual differences in the predisposition to obesity and type 2 diabetes remain obscure.
Obesity is characterized clinically by an increased fat mass and enhanced energy storage in adipose tissue 3 . Increases in fat can be caused by adipocyte hypertrophy or adipocyte hyperplasia 4 . The adipocytes in adipose tissue are derived from adipose-tissue-derived stromal cells (ADSCs) via specialized cell-lineage differentiation processes. ADSCs are mesenchymal stem cells derived from adipose tissues, and play a key role in the generation and metabolism of adipose tissues. The processes by which ADSCs differentiate into adipocytes can be thought of as a cascade, with three primary stages. During the first stage, ADSCs are committed to become adipocyte precursor cells, and these cells then differentiate into preadipocytes. During the second stage, the preadipocytes reach confluence and undergo growth arrest, after which clonal expansion is induced. During the final stage, the cells undergo terminal differentiation, which is driven by the expression of adipocyte-specific genes, to produce the adipocyte phenotype [5] [6] [7] . Therefore, one possible way to reduce the fat mass is to therapeutically regulate the differentiation process at a certain stage or to block the transition between those stages.
MicroRNAs (miRNAs) are a class of short noncoding RNAs, about 19-22 nucleotides in length, that can bind to complementary target sites in mRNA molecules, causing translation repression or the cleavage of the target mRNAs 8, 9 . Computational predictions suggest that 45,000 putative miRNA binding sites exist in human proteincoding genes 10 . However, many of these putative miRNA binding sites are yet to be validated experimentally. Over the past decade, miRNAs have been shown to play important regulatory roles in a variety of physiological processes 11, 12 , and some miRNAs are reported to accelerate or inhibit the processes of adipocyte differentiation during adipogenesis. Thereinto, miR-143 is one of the miRNAs that has already been studied. However, although several previous studies have found that miR-143 can promote adipocyte differentiation, the details of the regulatory mechanisms are obscure, and the target gene of miR-143 has not been persuasively identified 13, 14 .
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In this study, we systematically investigated the role of miR-143 during the adipogenic differentiation of ADSCs, which naturally differentiate into adipocytes within adipose tissues. We analyzed the miRNA expression profile during ADSC differentiation and found that the expression of miR-143 decreased during the first 2 days and then increased markedly. Next, we varied the levels of miR-143 in ADSCs using a lentivirus and measured their lipid accumulation and the expression of specific adipogenesis-related genes. Cell numbers and the cell cycle were also monitored to measure cell proliferation after induction. The overexpression of miR-143 in the first 2 days after induction, i.e., during the clonal expansion stage, inhibited cell proliferation and adipogenic differentiation, whereas the overexpression of miR-143 in the days that followed, i.e., during the growth arrest stage and terminal differentiation stage, promoted adipogenesis. However, cell proliferation and the cell cycle were unaffected. Further experiments suggested that miR-143 regulates adipogenesis by directly repressing mitogen-activated protein kinase kinase 5 (MAP2K5), a key member of the mitogen-activated protein kinase kinase (MAPKK) family in the MAPK signaling pathway.
Results
Expression of miR-143 during ADSC adipogenesis and in ADSCs infected with an miR-143-expressing lentivirus. We selected miR-143 for analysis because its expression level showed a significant change between pre-induction and post-induction in a previous microRNA microarray study, and using quantitative real-time PCR (RT-qPCR), determined its expression during the whole adipogenic differentiation process of ADSCs. We found that the expression of miR-143 decreased during the first 2 days after adipogenic induction, but increased from day 3 and peaked on day 7 after induction ( Figure 1A and 1C) . To investigate whether miR-143 plays a role in the molecular regulation of ADSC adipogenesis, ADSCs were transfected with a lentivirus vector expressing either miR-143 or an miR-143 antagomir. The efficiency of lentivirus transduction was determined with fluorescence microscopy ( Figure 1B) . A preliminary test showed that the expression of miR-143 during the first 48 h was maintained at a low level, but began to increase 48 h after transduction, peaking at 72 or 96 h, and then remained at a high level until day 7 ( Figure 1D ). The transfected cells were then induced with a cocktail of 0.5 mM 3-isobutyl-1-methylxanthine, 1 mM dexamethasone, and 5 mg/mL insulin (MDI) at 72 or 24 h after transduction. Accordingly, we found that the expression of miR-143 remained high from day 0 to day 7 after induction if the cells were induced 72 h after transduction, while the expression of miR-143 remained low in the first 2 days and increased from day 3 after induction if the cells were induced 24 h after transduction ( Figure 1E and 1F).
miR-143 inhibits ADSC differentiation when it is overexpressed during the first 2 days after induction. The ADSCs were adipogenic induced 72 h after lentivirus transduction, at which time the expression of miR-143 or the miR-143 antagomir peaked. Lipid accumulation was determined on day 7 after induction and the expression of two principal transcription factors involved in adipogenesis, CCAAT/enhancer binding protein a (C/EBP-a) and peroxisome proliferator-activated receptor c (PPAR-c), was detected with RTqPCR on days 0, 1, and 7. These results indicate that the cells in the miR-143 group produced significantly fewer lipid droplets, whereas the cells in the anti-miR-143 group, in which the expression of miR-143 was downregulated, accumulated significantly more lipid droplets (Figure 2A ). The RT-qPCR results showed that the levels of C/EBP-a and PPAR-c mRNAs were significantly lower in the miR-143 group and significantly higher in the anti-miR-143 group ( Figure 2B and 2C) . Similar results were obtained with a western blot analysis on day 7 after induction ( Figure 2D ).
Overexpression of miR-143 in the first 2 days after induction impairs the clonal expansion of ADSCs. The treatment of ADSCs with an adipogenic stimulus initiates a complex sequence of events, including clonal expansion, growth arrest, and terminal differentiation. Because the overexpression of miR-143 during the first 2 days after stimulation inhibited ADSC differentiation, we postulated that miR-143 might play an important role during the clonal expansion stage. To test this hypothesis, ADSCs were transfected with a lentiviral vector expressing either miR-143 or an miR-143 antagomir and allowed to reach confluence, at which point the adipogenic program was initiated using the MDI cocktail. A cell-cycle analysis showed that the overexpression of miR-143 caused an increase in the fraction of cells in the G 0 /G 1 phase and a reduction in the fraction in S phase ( Figure 3A and 3B), indicating that miR-143 induced a cell-cycle delay. A 3-(4,5-dimethylthizol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay showed that the cell numbers decreased in the miR-143 group and increased in the anti-miR-143 group compared with the number of untreated cells or in the cells transfected with the empty vector ( Figure 3C ). The cell proliferation test based on bromodeoxyuridine (BrdU) incorporation showed corresponding results ( Figure 3D and 3E). Taken together, these data support a role for miR-143 in blocking clonal expansion during adipogenesis.
miR-143 promotes ADSC differentiation when miR-143 is overexpressed after clonal expansion stage. To investigate whether miR-143 plays a role after clonal expansion stage (2 days after induction), adipogenic induction was initiated 24 h after transduction. At this time, the expression of miR-143 did not increase, whereas 72 h later, it reached a peak. Interestingly, the introduction of ectopic miR-143 at this time promoted ADSC differentiation to adipocytes, measured with Oil Red O staining ( Figure 4A ), and the mRNA levels of C/EBPa and PPAR-c were significantly higher in the cells transfected with miR-143 than in the control cells ( Figure 4B and 4C) on day 7 of differentiation. A western blot analysis also showed that the concentrations of active PPAR-c were higher in the cells transfected with miR-143 than in the cells transfected with the empty vector or miR-143 antagomir, whereas the concentrations of inactive phosphorylated PPAR-c (p-PPAR-c) decreased ( Figure 4D ). To test whether miR-143 is also involved in the clonal expansion stage of adipocyte differentiation, cell proliferation and the cell cycle were monitored again. Cell numbers, BrdU incorporation, and the cell cycle were not influenced by the ectopic overexpression of miR-143 ( Figure 4E , 4F, 4G, and 4H).
miR-143 may regulate ADSC differentiation by targeting the MAP2K5-ERK5 signaling pathway. To identify the target genes through which miR-143 exerts its effects on adipocyte differentiation, bioinformatics was used to predict and rank the putative miR-143 target genes related to adipogenesis. MAP2K5, which is an activated kinase in the MAPK signaling pathway, was predicted to be a target gene of miR-143 with both the miRanda and MicroCosm target prediction programs. The mRNA levels and protein levels of MAP2K5 were determined 1 day after adipogenesis induced with the MDI cocktail. The MAP2K5 mRNA levels were significantly reduced in the miR-143 group compared with those in the untreated group or the empty-vector-treated group, whereas they were increased in the anti-miR-143 group ( Figure 5A ). This is consistent with the results of a western blot analysis of the protein concentrations ( Figure 5C ). In supplementary studies, we also examined the mRNA and protein levels of extracellular signal-regulated kinase 5 (ERK5), which is the direct downstream of MAP2K5 and known to promote cell growth and proliferation in previous studies 15 . Both RT-qPCR and western blot analyses indicated that ERK5 expression was downregulated in cells overexpressing miR-143 ( Figure 5B and 5D ). To confirm that MAP2K5 is a direct target gene of miR-143, we used an enhanced green fluorescent protein (EGFP) reporter assay to www.nature.com/scientificreports demonstrate that MAP2K5 expression is directly inhibited by miR-143. An alignment of miR-143 and the MAP2K5 39-untranslated region (UTR) was constructed with bioinformatics and is illustrated in Figure 5E . When the 39-UTR sequence of MAP2K5 was then cloned downstream from the EGFP-coding sequence, EGFP expression was strongly reduced when miR-143 was overexpressed. To confirm the direct interaction between miR-143 and the MAP2K5 39-UTR, we introduced three mutations into the seed sequence of the MAP2K5 39-UTR and found that EGFP expression from the mutated vector (MpcDNA3-EGFP-E2F3) was not affected by miR-143 overexpression ( Figure 5F ). Taken together, these results strongly suggest that miR-143 regulates the adipogenic differentiation of ADSCs, at least in part, by targeting the 39-UTR of MAP2K5.
Discussion
Adipose tissue is not only a storage depot for triglycerides but also a functional organ with a role in regulating energy homeostasis. It is well known that abnormal fat accumulation is associated with adverse health outcomes, including obesity, type II diabetes, and cardiovascular and cerebrovascular diseases 16 . Therefore, a better understanding of the regulatory mechanisms of adipogenesis is crucial for the development of novel therapeutic strategies for these diseases. This is a complex physiological process, involving a large number of molecular events, and little is known about the precise mechanisms of adipogenesis. ADSCs, which act as somatic stem cells in adipose tissues, share many of the characteristics of their counterparts in the bone marrow, including extensive proliferative potential and the ability to differentiate into adipogenic, osteogenic, chondrogenic, and myogenic lineages [17] [18] [19] . Within the adipose tissues, adipocytes are derived from ADSCs via a specialized cell-lineage differentiation process, and ADSCs play a key role in the generation and metabolism of adipocyte tissues 5, 20 . In this study, the overexpression of miR-143 did not consistently promote or inhibit adipogenesis. When miR-143 was overexpressed during the clonal expansion stage, the adipogenic differentiation of ADSCs was inhibited. However, the expression of miR-143 increased after the clonal expansion stage, during the growth arrest stage and terminal differentiation, when differentiation was promoted. It is clear that during clonal expansion, growth-arrested cells re-enter the cell cycle and undergo several rounds of division, when DNA replication and changes in the chromatin structure increase the accessibility of cis-acting elements to trans-acting factors, triggering the expression of adipogenic-differentiation-related genes 21, 22 . Therefore, the reason of miR-143 inhibiting adipogenic differentiation during clonal expansion stage is that the miR-143-mediated inhibition of adipogenesis is caused by a block at the clonal expansion stage. But why the overexpression of miR-143 promotes differentiation at the point at which cells switch from clonal expansion to growth arrest and terminal differentiation stage aroused our curiosity.
It is widely acknowledged that the MAPK signaling pathway plays a pivotal role in many essential cellular processes, including cell proliferation and differentiation. The role of MAPKs in the process of adipocyte differentiation is extremely complex and depends on many parameters. The adipogenic differentiation process involves several successive steps, and each step may be modulated by MAPKs. In the clonal expansion stage, DNA synthesis and cell mitotic division require the activation of the MAPK signaling pathway, but in the terminal differentiation stage, the activation of MAPKs inhibits cell differentiation via the phosphorylation of PPAR-c 23, 24 . Therefore, we examined whether miR-143 regulates adipogenesis by acting on the MAPK signaling pathway.
It has been suggested, although rarely, that miRNAs regulate adipogenesis by acting on the MAPK signaling pathway 13, 25, 26 . Strikingly, one study showed that the inhibition of miR-143 blocked adipogenesis and increased the protein levels of ERK5, suggesting that miR-143 targets the ERK5 gene 13 . However, those data showed that miRNAs regulate adipogenesis by predominantly regulating MAPKs during the growth-arrested stage after clonal expansion, whereas the clonal expansion stage is unaffected. Therefore, further studies were required to clarify the direct role of miR-143 in the clonal expansion stage. Furthermore, the real target gene of miR-143 in adipogenesis had not been persuasively identified.
ERK5 is a member of the MAPK family, and has a Thr-Glu-Tyr (TEY) sequence in its dual phosphorylation site, like ERK1/2, which plays a significant role in cell growth and differentiation. This suggests that the regulation and function of ERK5 are similar to those of ERK1/2. This was confirmed by Kato and colleagues, who demonstrated that ERK5 is even more essential than ERK1/2 for cell proliferation and cell-cycle progression in response to tyrosine kinase signaling 15 .The upstream kinase that directly phosphorylates ERK5 was identified as MAP2K5 27, 28 . To determine whether miR-143 exerts its effects on adipocyte differentiation by targeting the MAPK signaling pathway, bioinformatics were used to predict and rank putative target genes related to both adipogenesis and the MAPK pathway in this study. MAP2K5 was predicted to be a target gene of miR-143 by both the miRanda and MicroCosm target prediction programs, and this was confirmed for the first time in an experimental assay in this study. Taken together, several results indicate that MAP2K5 mRNA is the direct target of miR-143. First, the 39-UTR of MAP2K5 contains a seed region that is complementary to the miR-143 sequence. Second, the overexpression of miR-143 suppressed the expression of the MAP2K5 protein, whereas the inhibition of miR-143 enhanced MAP2K5 expression. Third, the overexpression of miR-143 in 293T cells resulted in the reduced expression of a fluorescent reporter containing the MAP2K5 39-UTR. Fourth, specific mutations in the miR-143 target site within the MAP2K5 39-UTR of the reporter abolished its regulation by miR-143. Therefore, in this study, we have identified the direct target gene of miR-143 and clarified the involvement of ERK5 observed in previous studies.
The arguments discussed above suggest an explanation of the results of this study. During the clonal expansion stage, the overexpression of miR-143 suppresses the expression of MAP2K5. As the phosphorylation substrate for MAP2K5, activated ERK5 decreases, thus blocking clonal expansion. In rapid succession, C/EBP-a that triggered by DNA synthesis and changes in the chromatin structure during clonal expansion, is suppressed, and eventually leads to the inhibition of adipogenic differentiation. During the growth arrest and terminal differentiation stages, the overexpression of miR-143 blocks the MAP2K5-ERK5 signaling pathway, so the ERK5-mediated phosphorylation of PPAR-c is reduced. Consequently, more activated nonphosphorylated PPAR-c protein remains, so adipogenic differentiation is ultimately promoted ( Figure 6A ).
In a complementary study, we also examined the protein levels of MAP2K5 during ADSC differentiation. MAP2K5 was markedly induced 1 day after MDI treatment and peaked on days 2 or 3, slowly returning to the baseline level on day 5 ( Figure 6B) . Thus, when the data discussed above are considered together, we can see that MAP2K5 and miR-143 expression ( Figure 1C ) are inversely correlated. Induction of the adipogenic differentiation of ADSCs initially results in cell growth and clonal expansion, which require increased MAP2K5 expression, so the expression of miR-143 is reduced. However, when the cells switch from clonal expansion to the growth arrest and terminal differentiation stages, MAP2K5 expression must be inhibited, so the expression of miR-143 increases ( Figure 6C ).
In summary, we have provided evidence that miR-143 regulates adipocyte differentiation, and propose that miR-143 plays a partial role by directly targeting MAP2K5 mRNA, thereby promoting the transition from clonal expansion to terminal differentiation. Our findings suggest that miR-143 plays an important role in adipose tissue formation, with special implications for some metabolic disease in which the amount and/or function of adipose tissue is altered.
Methods
Cell isolation, culture, and differentiation. Normal female Sprague-Dawley rats (2 weeks old) were cared for and used in accordance with the International Guiding Principles for Animal Research. ADSCs were isolated from the inguinal fat tissues and validated by their multilineage differentiation potential, flow cytometry (CD29 1 , CD31 2 , and CD45
2 ), plastic adherence, and colony-forming ability, according to the methods described in our previous studies 29, 30 . The cells were then cultured in a-MEM with 10% fetal bovine serum in a humidified 5% CO 2 atmosphere. When the cells reached 80% confluence, a cocktail of 0.5 mM 3-isobutyl-1-methylxanthine, 1 mM dexamethasone, and 5 mg/mL insulin (MDI) was added to the culture medium to induce adipogenic differentiation. The induction medium was replaced every 72 h until the ADSCs had differentiated into mature adipocytes.
Oil Red O staining. When the ADSCs differentiated into mature adipocytes on day 7 following adipogenic induction, the cells were stained with Oil Red O. Briefly, the cells were washed twice with PBS and fixed in 4% paraformaldehyde at room temperature for 30 min. They were then washed three times with 70% isopropanol. Cell transduction assay. Second-passage ADSCs were plated in 12-well plates. When the ADSCs reached the optimal infection phase (30-50% confluence), the cells of the miR-143 group were infected with 4.2 mL of miR-143-lentivirus (titer, 1.2 3 10 9 TU/ mL; multiplicity of infection [MOI] 5 50), the cells of the anti-miR-143 group with 2 mL of anti-miR-143-lentivirus (titer, 2.5 3 10 9 TU/mL; MOI 5 50), and the cells in the empty-vector group were infected with 2.5 mL of the empty lentivirus vector (titer, 2 3 10 9 TU/mL; MOI 5 50) in individual wells. The untreated group was not infected with lentivirus. The cell culture medium was replaced 12 h after infection. Fluorescent protein expression in the ADSCs was observed using an inverted fluorescence microscope 24, 48, 72, and 96 h after infection to assess the infection efficiency. The highest level of fluorescent protein expression occurred 72 h after transduction. Each experiment in this study was performed after the transduction of the cells, and the adipogenic induction agent (MDI) was added when the confluence of the infected cells reached 80% (after 3-4 days in culture; the cells were not passaged).
Quantitative real-time PCR. mRNA was quantified using MMLV reverse transcriptase (Epicentre) and SYBR-Green-based quantitative PCR (qPCR) with an ABI PRISM 7500 system (Applied Biosystems). The qPCR reactions were performed with initial incubation at 95uC for 10 min followed by 40 cycles of 95uC for 10 s and 60uC for 60 s. The relative expression level of each miRNA was normalized to the level of GAPDH mRNA and calculated using the DDCt method. The following primer pairs were used for RT-qPCR: C/EBP-a, 59-CGGGAACGCAACAACATC-39 (forward) and 59-TCCAGCGACCCTAAACCAT-39 (reverse); PPAR-c, 59-CAGAG TCTGCTGATCTGCGAG-39 (forward) and 59-TGCAGGGGGGTGATATGTT-39 (reverse); MAP2K5, 59-GGAAGCAGCCCAAGGAA-39 (forward) and 59-CCAAT CAGGCAGCAGACAG-39 (reverse); ERK5, 59-TAGTGGGTTGCCTGGTTCTG-39 (forward) and 59-GTCTGCCTGGCTATCCTGTG-39 (reverse); and GAPDH, 59-GGAAAGCTGTGGCGTGAT-39 (forward) and 59-AAGGTGGAAGAATGG GAGTT-39 (reverse).
The miRNA concentrations were determined using TaqMan RT-qPCR. The PCR reactions were performed in a final volume of 20 mL using an ABI PRISM 7900 system (Applied Biosystems). Each reaction contained PCR primers, gene-specific stem-loop primers, and probes. The PCRs were performed with an initial incubation at 95uC for 10 min followed by 40 cycles of 95uC for 10 s and 60uC for 60 s. The absolute miRNA expression levels were normalized to an internal control (small nuclear U6) and calculated using the DDCt method. The primers and probes used were as follows: miR-143, 59-GTCGTATCCAGTGCGTGTCGTGGAGTCGGCAA TTGCACTGGATACGACTGAGCT-39 (RT primer), 59-GGCTGAGATGAAGCA CTGT-39 (gene-specific stem-loop primer), and 59-CAGTGCGTGTCGTGGAG-39 (probe); and U6, 59-GCTTCGGCAGCACATATACTAAAAT-39 (forward) and 59-CGCTTCACGAATTTGCGTGTCAT-39 (reverse).
Western blot analysis. Confluent ADSCs were treated under the appropriate conditions and lysed. The protein content of the lysate was determined using a protein assay kit (Bio-Rad Laboratories). The proteins were separated with 10% SDS-PAGE and transferred to cellulose membranes. The membranes were incubated with the following primary antibodies: anti-MAP2K5 (15500; Bioss), anti-phospho-ERK5 (15200; Bioss), anti-CEBP-a (15200; Sigma-Aldrich), anti-PPAR-c and antiphospho-PPAR-c (15500; Sigma-Aldrich), anti-b actin (151000; Santa Cruz Biotechnology), and anti-GAPDH (151000; Santa Cruz Biotechnology). Following overnight incubation with the primary antibodies, the membranes were immunoblotted with a horseradish-peroxidase-conjugated secondary antibody (155000; Santa Cruz Biotechnology). Immunoreactivity was visualized with enhanced chemiluminescence (ECL kit; Santa Cruz Biotechnology) and analyzed using the Quantity One system (Bio-Rad).
MTT assay and BrdU incorporation assay. An MTT assay was used to detect cell proliferation. On days 0, 1, 2, 3, and 4, ADSCs were transferred to 96-well plates and incubated for 2 h with MTT (5.0 mg/mL) at 37uC, followed by centrifugation. The supernatants were then removed, and 200 mL of dimethyl sulfoxide was added. The absorbance at 490 nm was measured. BrdU labeling was used to detect DNA synthesis. ADSCs from each group were cultured in 96-well plates and treated with BrdU (30 mg/mL) 24 h after induction. After the cells were labeled with BrdU for 2 h, the medium was removed and BrdU incorporation was measured using the BrdU Cell Proliferation ELISA Kit (Abcam). The reactions were stopped with 1 M H 2 SO 4 . Finally, the cells were examined under an inverted microscope, and the absorbance was measured by spectrophotometry at 450 nm.
Cell-cycle analysis. ADSCs from each group were harvested and washed with PBS. The cells were fixed with cold 70% ethanol for 2 h, treated with 1 mg/mL RNase A for 30 min at 37uC, and then stained with 20 mg/mL propidium iodide and subjected to cell-cycle analysis using flow cytometry (Beckman FC500). The results were analyzed with the WinMDI software.
Fluorescent reporter assay. The MicroCosm and miRanda target prediction programs recommended by miRBase were used to predict the adipogenesis-related target genes of miR-143. MAP2K5 was predicted as a target gene with a high probability score by both algorithms. The 39-UTR sequence of the MAP2K5 mRNA was acquired from the National Center for Biotechnology Information and the sequence of miR-143 from the miRBase. EGFP/RFP reporter vectors were constructed based on these data. 293T cells were then seeded in a 24-well plate at 30,000 cells per well the day before transduction. The cells were cotransfected with an miR-143 mimic or negative control oligonucleotide, and the following day with the reporter vector pcDNA3-EGFP-MAP2K5 39-UTR or the mutant pcDNA3-EGFP-MAP2K5 39-UTR. The reactions were spiked with the red fluorescent protein (RFP)-expressing vector pDsRed2-C1, which was used for normalization. The EGFP and RFP activities were measured 48 h after transduction with an F-4500 fluorescence spectrophotometer (Hitachi).
Statistical analysis. All quantitative data are expressed as means 6 standard deviations. One-way analysis of variance (ANOVA) was used to compare two groups in a single experiment and multiple comparisons, with the SPSS software program for Windows. A value of P , 0.05 or P , 0.01 was considered to be statistically significant. The statistically significance of microarray result was analyzed by fold change and the Student t test. The threshold value we used to screen differentially expressed miRNAs is a fold change $ 1.5 (P , 0.01, FDR , 0.05).
